Tirzepatide (Mounjaro, Zepbound) is one of the most effective weight loss medications available — but it is not instant. The medication uses a careful dose titration schedule that starts low and increases every 4 weeks. Understanding the timeline helps patients stay patient, set realistic expectations, and recognize when medication is or is not working as expected.
Tirzepatide Timeline: What to Expect
Starting Dose — Monitor Tolerability
The FDA Zepbound label uses 2.5 mg weekly for initiation. Appetite changes and gastrointestinal symptoms vary; a starting dose does not guarantee a particular effect. Report severe or persistent symptoms promptly.
First Dose Increase — Monitor Response
After 4 weeks on the starting dose, your provider may increase to 5 mg if you are tolerating the medication. Appetite, weight, and GI effects vary; your provider monitors response and adjusts the plan as clinically appropriate.
Reassess Response and Tolerability
Any further increase is individualized and should occur only as prescribed, after at least 4 weeks at the current dose. These weeks are not a guaranteed window for visible results.
Ongoing Treatment Review
The FDA label lists 5, 10 or 15 mg weekly as maintenance doses for weight management. Research published in the New England Journal of Medicine assessed outcomes over 72 weeks; reaching a maintenance dose does not establish that a patient's maximum benefit has occurred.
The "Not Working Yet" Trap
The most common mistake patients make with tirzepatide is giving up too early. The starting dose (2.5 mg) is intentionally low — designed to minimize side effects, not to produce maximum weight loss. Patients who judge tirzepatide by their first 2–4 weeks and conclude it is not working are almost always in the titration phase, not the therapeutic phase.
If you are seeing no appetite reduction whatsoever after 4–6 weeks at the starting dose, that is worth discussing with your provider — but mild results in the first weeks are completely normal and expected.
Individual Variation Is Real
The SURMOUNT clinical trials showed a mean weight loss of 15–22% — but that is a range across thousands of patients. Some patients lose significantly more; some less. Response timing also varies: some patients feel dramatic appetite suppression by week 2; others do not notice full effect until month 3 when they reach a higher dose.
Your provider tracks your progress throughout the program and adjusts your care plan based on your individual response — not a one-size-fits-all protocol.